Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17034253 | 0.81 | ALDH1A1 (0.40) | ALDH1A1SOAT1LMNACYP3A4ALOX15 | |
| SCHEMBL17032672 | 0.81 | TSHR (0.32) | LMNATSHR | |
| SCHEMBL5962989 | 0.80 | ALDH1A1 (0.46) | ALDH1A1SOAT1LMNACYP3A4ALOX15 | |
| SCHEMBL18307667 | 0.79 | ALDH1A1 (0.41) | ALDH1A1SOAT1LMNAALOX15 | |
| SCHEMBL14283708 | 0.79 | ALDH1A1 (0.44) | ALDH1A1SOAT1LMNACYP3A4ALOX15 | |
| SCHEMBL17034257 | 0.77 | ALDH1A1 (0.43) | ALDH1A1SOAT1LMNAALOX15 | |
| SCHEMBL18239576 | 0.76 | ALDH1A1 (0.41) | ALDH1A1SOAT1LMNAALOX15 | |
| SCHEMBL28404629 | 0.75 | ALDH1A1 (0.60) | ALDH1A1SOAT1LMNAALOX15TSHR | |
| SCHEMBL1469974 | 0.74 | ALDH1A1 (0.52) | ALDH1A1SOAT1LMNAALOX15 | |
| SCHEMBL13842304 | 0.72 | ALDH1A1 (0.50) | ALDH1A1SOAT1LMNAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170260219-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-9663543-B2 | Phosphonate compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160362432-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362432-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, CFH, TFPI | ALDH1A1 4266/4885SOAT1 850/4885LMNA 1699/4885 |
| US-20170260219-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, C1QBP | ALDH1A1 3727/4885SOAT1 1811/4885LMNA 1958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.